RBC Capital Believes Epizyme (NASDAQ: EPZM) Still Has Room to Grow

By Jason Carr

RBC Capital analyst Matthew Eckler reiterated a Buy rating on Epizyme (NASDAQ: EPZM) on September 14 and set a price target of $20. The company’s shares closed yesterday at $17.20, close to its 52-week high of $18.80.

According to TipRanks.com, Eckler is a 4-star analyst with an average return of 23.4% and a 88.9% success rate. Eckler covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Abeona Therapeutics, and Puma Biotechnology.

Epizyme has an analyst consensus of Strong Buy, with a price target consensus of $23.67.

The company has a one year high of $18.80 and a one year low of $8.38. Currently, Epizyme has an average volume of 732.3K.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Epizyme, Inc. operates as a clinical stage biopharmaceutical company. The company discovers, develops and plans to commercialize therapeutics for patients with genetically defined cancers. It engages in the creation of small molecule inhibitors of class of enzymes known as histone methyltransferases.